NCT07075419View on ClinicalTrials.gov

JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

August 1, 2027

Conditions
Refractory Hepatocellular Carcinoma
Interventions
DRUG

JDB153

JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerability assessment.

DRUG

Penpulimab

Penpulimab is administered by intravenous infusion at a dose of 200 mg once every 3 weeks (Q3W).

All Listed Sponsors
lead

West China Hospital

OTHER

NCT07075419 - JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure | Biotech Hunter | Biotech Hunter